natgillin/translations-raw huggingface dataset:
The Expert Committee considers that there is sufficient evidence that MPA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Stručni odbor smatra da ima dovoljno dokaza da se MPA zloupotrebljava ili da će se vjerojatno zloupotrebljavati te stoga predstavlja javnozdravstveni i društveni problem što opravdava njegovo stavljanje pod međunarodnu kontrolu.
Thus the WHO recommends that methiopropamine be placed in Schedule II under the Convention on Psychotropic Substances.
Zbog toga WHO preporučuje da se metiopropamin uvrsti u Tablicu II. Konvencije o psihotropnim tvarima.
MPA is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Europski centar za praćenje droga i ovisnosti o drogama prati metiopropamin kao novu psihoaktivnu tvar u skladu s Odlukom 2005/387/PUP.
MPA has been detected in 17 Member States.
Metiopropamin je otkriven u 17 država članica.
It has been associated with serious adverse events, including deaths.
Doveden je u vezu s događajima s teškim posljedicama, među kojima su i smrtni slučajevi.
Therefore, the Member States should take the position to add methiopropamine to Schedule II of the Convention on Psychotropic Substances.
Stoga bi države članice trebale zauzeti stajalište da se metiopropamin doda u Tablicu II. Konvencije o psihotropnim tvarima.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of MDMB-CHMICA (methyl N-[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl-3-methyl-L-valinate) is substantial.
Kako je procijenio Stručni odbor, zloupotreba tvari MDMB-CHMICA (metil N-[1-(cikloheksilmetil)-1H-indol-3-il]karbonil-3-metil-L-valinat) povezana je sa znatnim stupnjem rizika za javno zdravlje i društvo.
MDBD-CHMICA has no recorded therapeutic use.
Terapijska korist tvari MDMB-CHMICA nije zabilježena.
The Expert Committee recognises that MDBD-CHMICA has similar abuse to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Stručni odbor utvrdio je da MDMB-CHMICA ima potencijal za zloupotrebu i štetno djelovanje slično tvarima uvrštenim u Tablicu II. Konvencije o psihotropnim tvarima.
The Expert Committee considers that there is sufficient evidence that MDMB-CHMICA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Stručni odbor smatra da ima dovoljno dokaza da se MDMB-CHMICA zloupotrebljava ili da će se vjerojatno zloupotrebljavati te stoga predstavlja javnozdravstveni i društveni problem što opravdava njegovo stavljanje pod međunarodnu kontrolu.
Thus, the WHO recommends that MDMB-CHMICA be placed in Schedule II under the Convention on Psychotropic Substances.
Zbog toga WHO preporučuje da se MDMB-CHMICA uvrsti u Tablicu II. Konvencije o psihotropnim tvarima.
According to the risk assessment report of the European Monitoring Centre for Drugs and Drug Addiction, which was conducted under Article 6(2), (3) and (4) of Decision 2005/387/JHA and submitted on 28 July 2016 to the Commission and to the Council, the high potency of MDMB-CHMICA and the highly variable amounts of the compound in ‘legal high’ products constitute a high risk of acute toxicity.
Prema izvješću o procjeni rizika koje je Europski centar za praćenje droga i ovisnosti o drogama sastavio na temelju članka 6. stavaka 2., 3. i 4. Odluke 2005/387/PUP te 28. srpnja 2016. podnio Komisiji i Vijeću postoji velik rizik od akutne toksičnosti tvari MDMB-CHMICA zbog snažnog djelovanja te tvari te njezine vrlo promjenjive količine u „legalnim drogama”.
Eight Member States have reported a total of 28 deaths and 25 acute intoxications associated with MDMB-CHMICA.
Osam država članica izvijestilo je o ukupno 28 smrtnih slučajeva i 25 slučajeva akutnog trovanja povezanih s tvari MDMB-CHMICA.
The Commission therefore adopted on 31 August 2016 a proposal to subject MDMB-CHMICA to Union-wide control measures.
Komisija je stoga 31. kolovoza 2016. donijela prijedlog da se MDMB-CHMICA podvrgne kontrolnim mjerama unutar Unije.
Therefore, the Member States should take the position to add MDMB-CHMICA to Schedule II of the Convention on Psychotropic Substances.
Stoga bi države članice trebale zauzeti stajalište da se MDMB-CHMICA doda u Tablicu II. Konvencije o psihotropnim tvarima.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of 5F-APINACA or 5F-AKB-48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) is substantial.
Kako je procijenio Stručni odbor, zloupotreba tvari 5F-APINACA ili 5F-AKB-48 (N-(adamantan-1-il)-1-(5-fluoropentil)-1H-indazol-3-karboksamid) povezana je sa znatnim stupnjem rizika za javno zdravlje i društvo.
It has no recorded therapeutic use.
Terapijska korist tvari 5F-APINACA nije zabilježena.
The Expert Committee recognises that 5F-APINACA has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Stručni odbor utvrdio je da 5F-APINACA ima potencijal za zloupotrebu i štetno djelovanje slično tvarima uvrštenim u Tablicu II. Konvencije o psihotropnim tvarima.
The Expert Committee considers that there is sufficient evidence that 5F-APINACA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Stručni odbor smatra da ima dovoljno dokaza da se tvar 5F-APINACA zloupotrebljava ili da će se vjerojatno zloupotrebljavati te stoga predstavlja javnozdravstveni i društveni problem što opravdava njezino stavljanje pod međunarodnu kontrolu.
Thus, the WHO recommends that 5F-APINACA be placed in Schedule II under the Convention on Psychotropic Substances.
Zbog toga WHO preporučuje da se 5F-APINACA uvrsti u Tablicu II. Konvencije o psihotropnim tvarima.
5F-APINACA is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Europski centar za praćenje droga i ovisnosti o drogama prati 5F-APINACA kao novu psihoaktivnu tvar u skladu s Odlukom 2005/387/PUP.
5F-APINACA has been detected in 23 Member States.
5F-APINACA otkriven je u 23 države članice.
Therefore, the Member States should take the position to add 5F-APINACA to Schedule II of the Convention on Psychotropic Substances.
Stoga bi države članice trebale zauzeti stajalište da se 5F-APINACA doda u Tablicu II. Konvencije o psihotropnim tvarima.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of XLR-11 [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone is substantial.
Kako je procijenio Stručni odbor, zloupotreba tvari XLR-11 [1-(5-fluoropentil)-1H-indol-3-il](2,2,3,3-tetrametilciklopropil)metanon povezana je sa znatnim stupnjem rizika za javno zdravlje i društvo.
XLR-11 has no recorded therapeutic use.
Terapijska korist tvari XLR-11 nije zabilježena.
The Expert Committee recognises that XLR-11 has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances such as JWH-018 and AM-2201.
Stručni odbor utvrdio je da XLR-11 ima potencijal za zloupotrebu i štetno djelovanje slično tvarima JWH-018 i AM-2201 uvrštenim u Tablicu II. Konvencije o psihotropnim tvarima.
The Expert Committee considers that there is sufficient evidence that XLR-11 is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Stručni odbor smatra da ima dovoljno dokaza da se XLR-11 zloupotrebljava ili da će se vjerojatno zloupotrebljavati te stoga predstavlja javnozdravstveni i društveni problem što opravdava njegovo stavljanje pod međunarodnu kontrolu.
Thus, the WHO recommends that XLR-11 be placed in Schedule II under the Convention on Psychotropic Substances.
Zbog toga WHO preporučuje da se XLR-11 uvrsti u Tablicu II. Konvencije o psihotropnim tvarima.
XLR-11 is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Europski centar za praćenje droga i ovisnosti o drogama prati XLR-11 kao novu psihoaktivnu tvar u skladu s Odlukom 2005/387/PUP.
XLR-11 has been detected in 17 Member States.
XLR-11 otkriven je u 17 država članica.
It has been associated with small number of serious adverse events, including at least one death in which it was detected, and has been the subject of a public-health-related alert issued to the Union Early Warning System.
Doveden je u vezu s malim brojem događaja s teškim posljedicama, među ostalim je otkriven u najmanje jednom smrtnom slučaju, te je za njega izdano javnozdravstveno upozorenje u okviru sustava ranog upozoravanja u Uniji.
Therefore, the Member States should take the position to add XLR-11 to Schedule II of the Convention on Psychotropic Substances.
Stoga bi države članice trebale zauzeti stajalište da se XLR-11 doda u Tablicu II. Konvencije o psihotropnim tvarima.
Denmark is bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
Okvirna odluka 2004/757/PUP i Odluka 2005/387/PUP obvezujuće su za Dansku te ona stoga sudjeluje u donošenju i primjeni ove Odluke.
Ireland is bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
Okvirna odluka 2004/757/PUP i Odluka 2005/387/PUP obvezujuće su za Irsku te ona stoga sudjeluje u donošenju i primjeni ove Odluke.
The United Kingdom is not bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision, and is not bound by it or subject to its application,
Okvirna odluka 2004/757/PUP ni Odluka 2005/387/PUP nisu obvezujuće za Ujedinjenu Kraljevinu te ona stoga ne sudjeluje u donošenju ove Odluke, ona za nju nije obvezujuća niti se na nju primjenjuje,
The position to be adopted on the Union's behalf by the Member States in the Commission on Narcotic Drugs on 13 to 17 March 2017, when that body is called upon to adopt decisions on the addition of substances to the Schedules of the United Nations Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol and the United Nations Convention on Psychotropic Substances of 1971 at its 60th session, shall be in accordance with the Annex to this Decision.
Stajalište koje države članice trebaju zauzeti u ime Unije u okviru Komisije za opojne droge na njezinoj 60. sjednici od 13. do 17. ožujka 2017., kada će to tijelo odlučivati o dodavanju tvari u tablice u Jedinstvenoj konvenciji Ujedinjenih naroda o opojnim drogama iz 1961., kako je izmijenjena Protokolom iz 1972., i Konvenciji Ujedinjenih naroda o psihotropnim tvarima iz 1971., u skladu je s Prilogom ovoj Odluci.
The position shall be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union.
Djelujući zajednički u interesu Unije, stajalište izražavaju države članice koje su članice Komisije za opojne droge.
Position to be taken by the Member States which are members of the Commission on Narcotic Drugs acting jointly in the interest of the Union during the 60th session of the Commission on Narcotic Drugs on 13 to 17 March 2017 regarding changes in the scope of control of substances:
Stajalište koje države članice koje su članice Komisije za opojne droge trebaju zauzeti, djelujući zajednički u interesu Unije, na 60. sjednici Komisije za opojne droge od 13. do 17. ožujka 2017. u pogledu promjena opsega kontrole tvari:
U-47700 is to be included in Schedule I of the Single Convention of Narcotic Drugs of 1961 as amended by the 1972 Protocol.
U-47700 treba uvrstiti u Tablicu I. Jedinstvene konvencije o opojnim drogama iz 1961. kako je izmijenjena Protokolom iz 1972.
Butyrfentanyl is to be included in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol.
Butirfentanil treba uvrstiti Tablicu I. Jedinstvene konvencije o opojnim drogama iz 1961. kako je izmijenjena Protokolom iz 1972.
EC (4-methylethcathinone) is to be included in Schedule II of 1971 Convention on Psychotropic Substances.
EC (4-metiletkatinon) treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
Ethylone is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Etilon treba uvrstiti u Tabicu II. Konvencije o psihotropnim tvarima iz 1971.
Pentedrone (α-methylaminovalerophenone) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Pentedron (alfa-metilaminovalerofenon) treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
Ethylphenidate (EPH) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Etilfenidat (EPH) treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
MPA (methiopropamine) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Metiopropamin (MPA) treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
MDMB-CHMICA is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
MDMB-CHMICA treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
5F-APINACA (5F-AKB48) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
5F-APINACA (5F-AKB48) treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
XLR-11 is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
XLR-11 treba uvrstiti u Tablicu II. Konvencije o psihotropnim tvarima iz 1971.
The Expert Committee recognises that pentedrone has similar abuse to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Stručni odbor utvrdio je da pentadron ima potencijal za zloupotrebu i štetno djelovanje slično tvarima uvrštenim u Tablicu II. Konvencije o psihotropnim tvarima.
The Expert Committee considers that there is sufficient evidence that pentedrone is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Stručni odbor smatra da ima dovoljno dokaza da se pentedron zloupotrebljava ili da će se vjerojatno zloupotrebljavati te stoga predstavlja javnozdravstveni i društveni problem što opravdava njegovo stavljanje pod međunarodnu kontrolu.
Commission Implementing Decision (EU) 2017/450
Provedbena odluka Komisije (EU) 2017/450
of 13 March 2017
оd 13. ožujka 2017.
authorising the placing on the market of lactitol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
o odobravanju stavljanja na tržište laktitola kao novog sastojka hrane u skladu s Uredbom (EZ) br. 258/97 Europskog parlamenta i Vijeća
(notified under document C(2017) 1576)
(priopćeno pod brojem dokumenta C(2017) 1576)
On 16 March 2015, the company DuPont Nutrition Biosciences ApS made a request to the competent authorities of Denmark to place lactitol on the Union market as a novel food ingredient within the meaning of point (c) of Article 1(2) of Regulation (EC) No 258/97.
Društvo DuPont Nutrition Biosciences ApS podnijelo je 16. ožujka 2015. danskim nadležnim tijelima zahtjev za stavljanje na tržište Unije laktitola kao novog sastojka hrane u smislu članka 1. stavka 2. točke (c) Uredbe (EZ) br. 258/97.
In its request, the company proposes lactitol to be used in the same food categories and in the same use levels that are currently being used, when lactitol is added as a food additive under Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council [2].
U svojem zahtjevu društvo predlaže da se laktitol upotrebljava u istim kategorijama hrane i na istim razinama uporabe koje se trenutačno upotrebljavaju u slučajevima kada se laktitol dodaje kao prehrambeni aditiv u skladu s Prilogom II. Uredbi (EZ) br. 1333/2008 Europskog parlamenta i Vijeća [2].
On 1 July 2015, the competent food assessment body of Denmark issued its initial assessment report.
Nadležno tijelo za procjenu hrane u Danskoj izdalo je 1. srpnja 2015. izvješće o početnoj procjeni.
In that report it came to the conclusion that lactitol under the conditions of use proposed by the applicant meets the criteria for novel food ingredients set out in Article 3(1) of Regulation (EC) No 258/97.
U tom je izvješću zaključeno da, u uvjetima uporabe koje predlaže podnositelj zahtjeva, laktitol ispunjava kriterije za nove sastojke hrane utvrđene člankom 3. stavkom 1. Uredbe (EZ) br. 258/97.
On 13 July 2015, the Commission forwarded the initial assessment report to the other Member States.
Komisija je 13. srpnja 2015. izvješće o početnoj procjeni proslijedila ostalim državama članicama.
Some Member States made comments within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.
Neke su države članice iznijele primjedbe u propisanom roku od 60 dana iz članka 6. stavka 4. prvog podstavka Uredbe (EZ) br. 258/97.
Concerns were raised regarding the excess of lactitol intake and the possibility of misleading the consumer as the same uses and use levels are already authorised for lactitol as a food additive.
Izražena je zabrinutost u pogledu prevelikog unosa laktitola i mogućnosti zavaravanja potrošača, s obzirom na to da su iste uporabe i iste razine uporabe već odobrene za laktitol kao prehrambeni aditiv.
In the light of the Member States' comments, the competent authorities of Denmark reviewed the initial assessment report and concluded that an additional assessment was required in accordance with Article 7 of Regulation (EC) No 258/97.
U kontekstu primjedbi država članica danska su nadležna tijela revidirala izvješće o početnoj procjeni i zaključila da je potrebna dodatna procjena u skladu s člankom 7. Uredbe (EZ) br. 258/97.
That report takes into account the concerns regarding the excess of lactitol intake and the possibility of misleading the consumer and therefore gives sufficient grounds to restrict the use of lactitol to food supplements only and to establish that lactitol used in food supplements intended for adults is safe under the proposed conditions of use.
U tom se izvješću uzima u obzir zabrinutost u pogledu prevelikog unosa laktitola i mogućnosti zavaravanja potrošača i stoga daje dovoljno razloga da se uporaba laktitola ograniči isključivo na dodatke prehrani te utvrdi da je njegova uporaba u dodacima prehrani za odrasle u predloženim uvjetima uporabe sigurna.
Directive 2002/46/EC of the European Parliament and of the Council [3] lays down requirements for food supplements.
Direktivom 2002/46/EZ Europskog parlamenta i Vijeća [3] utvrđeni su zahtjevi o dodacima prehrani.
The use of lactitol should be authorised without prejudice to the provisions of that Directive.
Uporabu laktitola trebalo bi odobriti ne dovodeći u pitanje odredbe iz te Direktive.
Without prejudice to Directive 2002/46/EC, lactitol as specified in the Annex to this Decision may be placed on the market in the Union as a novel food ingredient to be used in food supplements in capsule or tablet form intended for the adult population with a maximum dose of 20 g lactitol per day as recommended by the manufacturer.
Ne dovodeći u pitanje Direktivu 2002/46/EZ, laktitol, kako je utvrđeno u Prilogu ovoj Odluci, može se staviti na tržište Unije kao novi sastojak hrane za uporabu u dodacima prehrani u obliku kapsula ili tableta namijenjenima populaciji odraslih u najvećoj dopuštenoj količini od 20 g laktitola na dan prema preporuci proizvođača.
The designation of lactitol authorised by this Decision on the labelling of the foodstuffs containing it shall be ‘lactitol’.
Oznaka laktitola koja se ovom Odlukom odobrava za uporabu na etiketi hrane koja ga sadržava jest „laktitol”.
This Decision is addressed to DuPont Nutrition Biosciences ApS, Langebrogade 1, PO Box 17, DK-1001, Copenhagen, Denmark
Ova je Odluka upućena društvu DuPont Nutrition Biosciences ApS, Langebrogade 1, PO Box 17, DK-1001, Kopenhagen, Danska
SPECIFICATION OF LACTITOL
SPECIFIKACIJA LAKTITOLA
Identity of lactitol
Identifikacija laktitola
β-D-Galactopyranosyl-D-glucitol
β-D-galaktopiranozil-D-glucitol
344,31 g/mol
344,31 g/mol
Description: Crystalline powder or colourless solution manufactured via catalytic hydrogenation of lactose.
Opis: Kristalni prah ili bezbojna otopina dobivena katalitičkom hidrogenacijom laktoze.
Crystalline products occur in anhydrous, monohydrate and dihydrate forms.
Kristalni produkti javljaju se u bezvodnom, monohidratnom i dihidratnom obliku.
Nickel is used as a catalyst.
Nikal se koristi kao katalizator.
Solubility (in water)
Topljivost (u vodi)
Very soluble in water
Vrlo topljiv u vodi
D20 = + 13° to + 16°
D20 = od + 13° do + 16°
Not less than 95 % d.b [1]
Najmanje 95 % ST [1]
Not more than 10,5 %
Najviše 10,5 %
Other polyols
Ostali polioli
Not more than 2,5 % d.b
Najviše 2,5 % ST
Not more than 0,2 % d.b
Najviše 0,2 % ST
Not more than 100 mg/kg d.b
Najviše 100 mg/kg ST
Not more than 200 mg/kg d.b
Najviše 200 mg/kg ST
Not more than 0,1 % d.b
Najviše 0,1 % ST
Not more than 2 mg/kg d.b
Najviše 2 mg/kg ST
Not more than 3 mg/kg d.b
Najviše 3 mg/kg ST
Not more than 1 mg/kg d.b
Najviše 1 mg/kg ST
d.b expressed on the dry weight basis
„ST”izraženo na temelju mase suhe tvari.
Commission Decision (EU) 2017/451
Odluka Komisije (EU) 2017/451
of 14 March 2017
оd 14. ožujka 2017.
approving, on behalf of the European Union, certain amendments to the Protocol setting out the fishing opportunities and financial contribution provided for in the Fisheries Partnership Agreement between the European Community and the Islamic Republic of Mauritania
o odobravanju, u ime Europske unije, određenih izmjena Protokola o utvrđivanju ribolovnih mogućnosti i financijskog doprinosa predviđenih Sporazumom o partnerstvu u ribarstvu između Europske zajednice i Islamske Republike Mauritanije
Having regard to Council Decision (EU) 2016/870 of 24 May 2016 on the conclusion, on behalf of the European Union, of the Protocol setting out the fishing opportunities and financial contribution provided for in the Fisheries Partnership Agreement between the European Community and the Islamic Republic of Mauritania for a period of four years [1], and in particular Article 3 thereof,
uzimajući u obzir Odluku Vijeća (EU) 2016/870 od 24. svibnja 2016. o sklapanju, u ime Europske unije, Protokola o utvrđivanju ribolovnih mogućnosti i financijskog doprinosa predviđenih Sporazumom o partnerstvu u ribarstvu između Europske zajednice i Islamske Republike Mauritanije za razdoblje od četiri godine [1], a posebno njezin članak 3.,
Article 10 of the Fisheries Partnership Agreement between the European Community and the Islamic Republic of Mauritania [2], hereinafter referred to as ‘the Agreement’, approved by Council Regulation (EC) No 1801/2006 [3], establishes a Joint Committee responsible for monitoring the application of the Agreement and, in particular, for supervising the implementation, interpretation and smooth operation thereof, as well as for reassessing, where appropriate, the level of fishing opportunities and, consequently, of the financial contribution.
Člankom 10. Sporazuma o partnerstvu u ribarstvu između Europske zajednice i Islamske Republike Mauritanije [2], dalje u tekstu: „Sporazum”, odobrenog Uredbom Vijeća (EZ) br. 1801/2006 [3], osnovan je Zajednički odbor nadležan za praćenje primjene navedenog Sporazuma, a posebno nadgledanje njegove provedbe, tumačenja i neometanog provođenja, te, prema potrebi, ponovno ocjenjivanje razine ribolovnih mogućnosti, a time i financijskog doprinosa.